Ngoc-Thanh-Van Nguyen1,2,3, Diep Tuan Tran4, Pham Le An5, Sy Van Hoang1,3,6, Hoai-An Nguyen4, Hoa Ngoc Chau1,2,3. 1. Division of Cardiology, Internal Medicine Department, University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh city 700 000, Vietnam. 2. Cardiology Department, Nhan Dan Gia Dinh Hospital, Ho Chi Minh city 700 000, Vietnam. 3. Outpatient Department, University Medical Center, Ho Chi Minh city 700 000, Vietnam. 4. University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh city 700 000, Vietnam. 5. Family Physician Training Center, University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh city 700 000, Vietnam. 6. Cardiology Department, Cho Ray Hospital, Ho Chi Minh city 700 000, Vietnam.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a rising health problem with heterogeneous presentation and no evidence-based treatment. While Southeast Asia reported the highest mortality and morbidity among Asian population, little is known about the Vietnamese population, including patient characteristics, prescribing pattern and mortality rate. METHODS: We conducted an observational study on 477 patients diagnosed with HFpEF from seven hospitals in Southern Vietnam from January 2019 to December 2019. RESULTS: Mean age was 67.6 (40.9% < 65 years). 62.3% were female. 82.4% were diagnosed within 5 years. Dyspnea, congestion, and hypoperfusion on admission were noted in 63.9%, 48.8%, and 4.6% of the patients, respectively. Median ejection fraction was 63%. Valvular heart disease (VHD) was the leading cause of heart failure (35.9%). 78.6% had at least two comorbidities, mostly hypertension (68.6%). 30.6% of the patients were hospitalized, with a median stay of 7.0 (4.0-10.0) days and inhospital mortality of 4.8%. Older patients (≥65 years) were more likely to be females (OR = 1.52); had multimorbid conditions (OR = 3.14), including hypertension (OR = 4.28), diabetes (OR = 1.73), coronary artery disease (CAD) (OR = 2.50), dyslipidemia (OR = 1.94), and chronic kidney disease (OR = 2.44); and were more frequently prescribed statin (OR = 3.15). Younger individuals (<65 years) were associated with higher mineralocorticoid antagonist uptake (OR = 0.52) and VHD (OR = 0,40). Prescription rate for renin-angiotensin-aldosterone system inhibitor, beta blocker, mineralocorticoid antagonist, and loop diuretic was 72.5%, 59.1%, 43.0%, and 60.6%, respectively. Four phenotypes were identified, including the lean/elderly/multimorbid; congestive/metabolic; CAD-induced; and younger/atrial fibrillation (AF)/VHD. The novel phenotype "younger/AF/VHD" exhibited high symptom burden and poor functional capacity despite being the youngest and least multimorbid. The "lean/elderly/multimorbid" phenotype demonstrated the highest symptom severity and inhospital mortality. CONCLUSIONS: Our research highlights a younger, predominantly female population with high disease burden. The four novelly identified phenotypes provide contemporary and pragmatic insights into a phenotype-guided approach, exclusively targeting the Vietnamese population.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a rising health problem with heterogeneous presentation and no evidence-based treatment. While Southeast Asia reported the highest mortality and morbidity among Asian population, little is known about the Vietnamese population, including patient characteristics, prescribing pattern and mortality rate. METHODS: We conducted an observational study on 477 patients diagnosed with HFpEF from seven hospitals in Southern Vietnam from January 2019 to December 2019. RESULTS: Mean age was 67.6 (40.9% < 65 years). 62.3% were female. 82.4% were diagnosed within 5 years. Dyspnea, congestion, and hypoperfusion on admission were noted in 63.9%, 48.8%, and 4.6% of the patients, respectively. Median ejection fraction was 63%. Valvular heart disease (VHD) was the leading cause of heart failure (35.9%). 78.6% had at least two comorbidities, mostly hypertension (68.6%). 30.6% of the patients were hospitalized, with a median stay of 7.0 (4.0-10.0) days and inhospital mortality of 4.8%. Older patients (≥65 years) were more likely to be females (OR = 1.52); had multimorbid conditions (OR = 3.14), including hypertension (OR = 4.28), diabetes (OR = 1.73), coronary artery disease (CAD) (OR = 2.50), dyslipidemia (OR = 1.94), and chronic kidney disease (OR = 2.44); and were more frequently prescribed statin (OR = 3.15). Younger individuals (<65 years) were associated with higher mineralocorticoid antagonist uptake (OR = 0.52) and VHD (OR = 0,40). Prescription rate for renin-angiotensin-aldosterone system inhibitor, beta blocker, mineralocorticoid antagonist, and loop diuretic was 72.5%, 59.1%, 43.0%, and 60.6%, respectively. Four phenotypes were identified, including the lean/elderly/multimorbid; congestive/metabolic; CAD-induced; and younger/atrial fibrillation (AF)/VHD. The novel phenotype "younger/AF/VHD" exhibited high symptom burden and poor functional capacity despite being the youngest and least multimorbid. The "lean/elderly/multimorbid" phenotype demonstrated the highest symptom severity and inhospital mortality. CONCLUSIONS: Our research highlights a younger, predominantly female population with high disease burden. The four novelly identified phenotypes provide contemporary and pragmatic insights into a phenotype-guided approach, exclusively targeting the Vietnamese population.
Authors: Ingrid E M Bank; Crystel M Gijsberts; Tiew-Hwa K Teng; Lina Benson; David Sim; Poh Shuan Daniel Yeo; Hean Yee Ong; Fazlur Jaufeerally; Gerard K T Leong; Lieng H Ling; A Mark Richards; Dominique P V de Kleijn; Ulf Dahlström; Lars H Lund; Carolyn S P Lam Journal: JACC Heart Fail Date: 2017-01 Impact factor: 12.035
Authors: Anders Mälarstig; Daniel Ziemek; Lars Lund; Åsa K Hedman; Camilla Hage; Anil Sharma; Mary Julia Brosnan; Leonard Buckbinder; Li-Ming Gan; Sanjiv J Shah; Cecilia M Linde; Erwan Donal; Jean-Claude Daubert Journal: Heart Date: 2020-01-07 Impact factor: 5.994
Authors: Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Jasper Tromp; Tiew-Hwa Teng; Wan Ting Tay; Chung Lieh Hung; Calambur Narasimhan; Wataru Shimizu; Sang Weon Park; Houng Bang Liew; Tachapong Ngarmukos; Eugene B Reyes; Bambang B Siswanto; Cheuk-Man Yu; Shu Zhang; Jonathan Yap; Michael MacDonald; Lieng Hsi Ling; Kirsten Leineweber; A Mark Richards; Michael R Zile; Inder S Anand; Carolyn S P Lam Journal: Eur J Heart Fail Date: 2018-08-16 Impact factor: 15.534
Authors: Jasper Tromp; Li Shen; Pardeep S Jhund; Inder S Anand; Peter E Carson; Akshay S Desai; Christopher B Granger; Michel Komajda; Robert S McKelvie; Marc A Pfeffer; Scott D Solomon; Lars Køber; Karl Swedberg; Michael R Zile; Bertram Pitt; Carolyn S P Lam; John J V McMurray Journal: J Am Coll Cardiol Date: 2019-08-06 Impact factor: 24.094
Authors: Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel Journal: J Am Heart Assoc Date: 2016-01-25 Impact factor: 5.501